ReviewCirculation research2010
Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern?
Review in Circulation research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- MiRNA Regulations in Cardiotoxicity Induced by Oncologic Therapies and Possible Immune Response.Current medicinal chemistry · 2026Review
- Mutational analysis of the mitochondrial tRNA genes and flanking regions in lymphocytes from long-term pediatric cancer survivors given doxorubicin chemotherapy for acute lymphoblastic leukemia.Cardio-oncology (London, England) · 2025Article
- Induction of the ER stress response in NRVMs is linked to cardiotoxicity caused by celastrol.Acta biochimica et biophysica Sinica · 2022Article
- Inhibition of the Phospholipase Cε-c-Jun N-Terminal Kinase Axis Suppresses Glioma Stem Cell Properties.International journal of molecular sciences · 2022Article
- Cyanine conjugates in cancer theranostics.Bioactive materials · 2021Review
- Natural and Synthetic Lactones Possessing Antitumor Activities.International journal of molecular sciences · 2021Review
- Inspired by Sea Urchins: Warburg Effect Mediated Selectivity of Novel Synthetic Non-Glycoside 1,4-Naphthoquinone-6S-Glucose Conjugates in Prostate Cancer.Marine drugs · 2020Article
- Phosphoinositide-Dependent Signaling in Cancer: A Focus on Phospholipase C Isozymes.International journal of molecular sciences · 2020Review
- Targeting transcription factors in cancer drug discovery.Exploration of targeted anti-tumor therapy · 2020Review
- Cardiovascular and Cancer Risk: The Role of Cardio-oncology.Journal of the advanced practitioner in oncology · 2018Review
- Review
- Cardiomyocyte ryanodine receptor degradation by chaperone-mediated autophagy.Cardiovascular research · 2013Article
- Trials with 'epigenetic' drugs: an update.Molecular oncology · 2012Review
- Cardiac side effects of anticancer treatments: new mechanistic insights.Current heart failure reports · 2012Review
- Lifestyle interventions for cardiovascular risk reduction in women with breast cancer.Current cardiology reviews · 2011Review
- How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?British journal of pharmacology · 2011Review
- Distal Medullary Canal Decompression in Long Stem Hip Replacement in Long Bone Metastasis: Does it Reduce Cardiopulmonary Complications?Indian journal of orthopaedicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The race for a cure to cancer continues, fueled by unprecedented discoveries of fundamental biology underlying carcinogenesis and tumorigenesis. The expansion of the target list and tools to approach them is moving the oncology community extraordinarily rapidly to clinical trials, bringing new hope for cancer patients. This effort is also propelling biological discoveries in cardiovascular research, because many of the targets being explored in cancer play fundamental roles in the heart and vasculature. The combined efforts of cardiovascular and cancer biologists, along with clinical investigators in these fields, will be needed to understand how to safely exploit these efforts. Here, we discuss a few of the many research foci in oncology where we believe such collaboration will be particularly important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.